{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:01:05Z","timestamp":1792119665079,"version":"4.4.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"National Science Center of Poland","doi-asserted-by":"publisher","award":["2012\/07\/B\/NZ7\/04253"],"award-info":[{"award-number":["2012\/07\/B\/NZ7\/04253"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Reports"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.pharep.2015.07.006","type":"journal-article","created":{"date-parts":[[2015,8,5]],"date-time":"2015-08-05T23:44:20Z","timestamp":1438818260000},"page":"127-138","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":407,"title":["Therapeutic strategies for Alzheimer's disease in clinical trials"],"prefix":"10.1007","volume":"68","author":[{"given":"Justyna","family":"Gody\u0144","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Jo\u0144czyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawid","family":"Panek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Malawska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"Part A","key":"10.1016\/j.pharep.2015.07.006_bib0520","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuropharm.2013.07.004","article-title":"Therapeutics of Alzheimer's disease: past, present and future","volume":"76","author":"Anand","year":"2014","journal-title":"Neuropharmacology"},{"issue":"9503","key":"10.1016\/j.pharep.2015.07.006_bib0525","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/S0140-6736(05)67889-0","article-title":"Global prevalence of dementia: a Delphi consensus study","volume":"366","author":"Ferri","year":"2005","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0530","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jalz.2012.11.006","article-title":"Alzheimer Disease international. The worldwide economic impact of dementia 2010","volume":"9","author":"Wimo","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"3","key":"10.1016\/j.pharep.2015.07.006_bib0535","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","article-title":"Epidemiology of Alzheimer disease","volume":"7","author":"Reitz","year":"2011","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.pharep.2015.07.006_bib0540","doi-asserted-by":"crossref","first-page":"535","DOI":"10.2147\/CIA.S51571","article-title":"The genetics of Alzheimer's disease","volume":"9","author":"Bagyinszky","year":"2014","journal-title":"Clin Interv Aging"},{"issue":"4","key":"10.1016\/j.pharep.2015.07.006_bib0545","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.bcp.2014.01.009","article-title":"The complexities of the pathology\u2013pathogenesis relationship in Alzheimer disease","volume":"88","author":"Castellani","year":"2014","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.pharep.2015.07.006_bib0550","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/joim.12192","article-title":"Pathways to Alzheimer's disease","volume":"275","author":"Hardy","year":"2014","journal-title":"J Intern Med"},{"issue":"8000","key":"10.1016\/j.pharep.2015.07.006_bib0555","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S0140-6736(76)91936-X","article-title":"Selective loss of central cholinergic neurons in Alzheimer's disease","volume":"2","author":"Davies","year":"1976","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.pharep.2015.07.006_bib0560","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.2165\/00003495-200666110-00015","article-title":"Memantine: a review of its use in Alzheimer's disease","volume":"66","author":"Robinson","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.pharep.2015.07.006_bib0565","first-page":"1471","article-title":"Disease-modifying drugs in Alzheimer's disease","volume":"7","author":"Ghezzi","year":"2013","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"10.1016\/j.pharep.2015.07.006_bib0570","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3346\/jkms.2014.29.7.893","article-title":"Diverse molecular targets for therapeutic strategies in Alzheimer's disease","volume":"29","author":"Han","year":"2014","journal-title":"J Kor Med Sci"},{"key":"10.1016\/j.pharep.2015.07.006_bib0575","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3389\/fphar.2014.00102","article-title":"The battle of Alzheimer's Disease \u2013 the beginning of the future unleashing the potential of academic discoveries","volume":"5","author":"Lundkvist","year":"2014","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.pharep.2015.07.006_bib0580","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J Intern Med"},{"key":"10.1016\/j.pharep.2015.07.006_bib0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/PMC.S13210","article-title":"New approaches to treating Alzheimer's disease","volume":"7","author":"Zheng","year":"2015","journal-title":"Perspect Med Chem"},{"issue":"4","key":"10.1016\/j.pharep.2015.07.006_bib0590","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.bcp.2013.12.020","article-title":"Immunotherapy for Alzheimer's disease","volume":"88","author":"Wisniewski","year":"2014","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pharep.2015.07.006_bib0595","doi-asserted-by":"crossref","first-page":"837157","DOI":"10.1155\/2014\/837157","article-title":"Potential therapeutic strategies for Alzheimer's disease targeting or beyond beta-amyloid: insights from clinical trials","volume":"2014","author":"Jia","year":"2014","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.pharep.2015.07.006_bib0600","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","article-title":"Ekavali. A review on Alzheimer's disease pathophysiology and its management: an update","volume":"67","author":"Kumar","year":"2015","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.pharep.2015.07.006_bib0605","article-title":"ATP leakage induces P2XR activation and contributes to acute synaptic excitotoxicity induced by soluble oligomers of beta-amyloid peptide in hippocampal neurons","author":"Saez-Orellana","year":"2015","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0610","doi-asserted-by":"crossref","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"1 (Suppl. 1)","key":"10.1016\/j.pharep.2015.07.006_bib0615","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1017\/S1092852900025876","article-title":"The pathogenesis of Alzheimer's disease and the role of Abeta42","volume":"12","author":"Golde","year":"2007","journal-title":"CNS Spectr"},{"issue":"9","key":"10.1016\/j.pharep.2015.07.006_bib0620","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer's disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.pharep.2015.07.006_bib0625","doi-asserted-by":"crossref","first-page":"a006387","DOI":"10.1101\/cshperspect.a006387","article-title":"Treatment strategies targeting amyloid beta-protein","volume":"2","author":"Schenk","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"10.1016\/j.pharep.2015.07.006_bib0630","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/joim.12168","article-title":"Amyloid-ss-directed immunotherapy for Alzheimer's disease","volume":"275","author":"Lannfelt","year":"2014","journal-title":"J Intern Med"},{"issue":"5","key":"10.1016\/j.pharep.2015.07.006_bib0635","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/path.4491","article-title":"Effect of active Abeta immunotherapy on neurons in human Alzheimer's disease","volume":"235","author":"Paquet","year":"2015","journal-title":"J Pathol"},{"issue":"2","key":"10.1016\/j.pharep.2015.07.006_bib0640","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/YCO.0000000000000041","article-title":"Is there still any hope for amyloid-based immunotherapy for Alzheimer's disease?","volume":"27","author":"Panza","year":"2014","journal-title":"Curr Opin Psychiatry"},{"issue":"3","key":"10.1016\/j.pharep.2015.07.006_bib0645","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1586\/1744666X.2014.883921","article-title":"Amyloid-based immunotherapy for Alzheimer's disease in the time of prevention trials: the way forward","volume":"10","author":"Panza","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"issue":"7","key":"10.1016\/j.pharep.2015.07.006_bib0650","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1474-4422(12)70140-0","article-title":"Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study","volume":"11","author":"Winblad","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.pharep.2015.07.006_bib0655","unstructured":"https:\/\/clinicaltrials.gov"},{"issue":"4","key":"10.1016\/j.pharep.2015.07.006_bib0660","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jalz.2013.05.564","volume":"9","author":"Arai","year":"2013","journal-title":"Alzheimer's Dement"},{"issue":"4","key":"10.1016\/j.pharep.2015.07.006_bib0665","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.pharep.2015.07.006_bib0670","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/alzrt249","article-title":"Modulation of beta-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study","volume":"6","author":"Leyhe","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"Suppl 1","key":"10.1016\/j.pharep.2015.07.006_bib0675","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1007\/s10875-014-0041-4","article-title":"Clinical trials of intravenous immunoglobulin for Alzheimer's disease","volume":"34","author":"Relkin","year":"2014","journal-title":"J Clin Immunol"},{"issue":"12","key":"10.1016\/j.pharep.2015.07.006_bib0680","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.bbamem.2013.06.005","article-title":"gamma-Secretase inhibitors and modulators","volume":"1828","author":"Golde","year":"2013","journal-title":"Biochim Biophys Acta"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0685","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/jcpt.12112","article-title":"Potential novel targets for Alzheimer pharmacotherapy: II. Update on secretase inhibitors and related approaches","volume":"39","author":"Mikulca","year":"2014","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0690","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3233\/JAD-2011-101065","article-title":"The many substrates of presenilin\/gamma-secretase","volume":"25","author":"Haapasalo","year":"2011","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.pharep.2015.07.006_bib0695","first-page":"115","article-title":"Neuropathological and biochemical assessments of an Alzheimer's disease patient treated with the gamma-secretase inhibitor semagacestat","volume":"3","author":"Roher","year":"2014","journal-title":"Am J Neurodegener Dis"},{"issue":"4","key":"10.1016\/j.pharep.2015.07.006_bib0700","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1210951","article-title":"A phase 3 trial of semagacestat for treatment of Alzheimer's disease","volume":"369","author":"Doody","year":"2013","journal-title":"N Engl J Med"},{"issue":"5415","key":"10.1016\/j.pharep.2015.07.006_bib0705","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.284.5415.770","article-title":"Notch signaling: cell fate control and signal integration in development","volume":"284","author":"Artavanis-Tsakonas","year":"1999","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.pharep.2015.07.006_bib0710","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1016\/j.jaad.2012.07.012","article-title":"Exacerbation of psoriatic skin lesions in a patient with Alzheimer disease receiving gamma-secretase inhibitor","volume":"68","author":"Hsu","year":"2013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0715","doi-asserted-by":"crossref","first-page":"54","DOI":"10.2174\/156802608783334015","article-title":"Therapeutic potential of gamma-secretase inhibitors and modulators","volume":"8","author":"Imbimbo","year":"2008","journal-title":"Curr Top Med Chem"},{"issue":"5799","key":"10.1016\/j.pharep.2015.07.006_bib0720","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1126\/science.1132341","article-title":"Control of peripheral nerve myelination by the beta-secretase BACE1","volume":"314","author":"Willem","year":"2006","journal-title":"Science"},{"issue":"2\u20133","key":"10.1016\/j.pharep.2015.07.006_bib0725","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000354233","article-title":"ADAM10 in synaptic physiology and pathology","volume":"13","author":"Musardo","year":"2014","journal-title":"Neurodegener Dis"},{"issue":"3","key":"10.1016\/j.pharep.2015.07.006_bib0730","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S1474-4422(13)70276-X","article-title":"Targeting the beta secretase BACE1 for Alzheimer's disease therapy","volume":"13","author":"Yan","year":"2014","journal-title":"Lancet Neurol"},{"issue":"9","key":"10.1016\/j.pharep.2015.07.006_bib0735","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-014-0089-7","article-title":"BACE1 inhibitor drugs in clinical trials for Alzheimer's disease","volume":"6","author":"Vassar","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"5 SUPPL","key":"10.1016\/j.pharep.2015.07.006_bib0740","doi-asserted-by":"crossref","first-page":"S411","DOI":"10.1016\/j.jalz.2013.11.004","article-title":"Lessons from a BACE1 inhibitor trial: off-site but not off base","volume":"10","author":"Lahiri","year":"2014","journal-title":"Alzheimers Dement"},{"issue":"14","key":"10.1016\/j.pharep.2015.07.006_bib0745","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1038\/emboj.2012.173","article-title":"Secretome protein enrichment identifies physiological BACE1 protease substrates in neurons","volume":"31","author":"Kuhn","year":"2012","journal-title":"EMBO J"},{"issue":"7409","key":"10.1016\/j.pharep.2015.07.006_bib0750","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature11283","article-title":"A mutation in APP protects against Alzheimer's disease and age-related cognitive decline","volume":"488","author":"Jonsson","year":"2012","journal-title":"Nature"},{"issue":"77","key":"10.1016\/j.pharep.2015.07.006_bib0755","doi-asserted-by":"crossref","first-page":"77sr1","DOI":"10.1126\/scitranslmed.3002369","article-title":"Alzheimer's disease: the challenge of the second century","volume":"3","author":"Holtzman","year":"2011","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.pharep.2015.07.006_bib0760","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00401-014-1371-2","article-title":"Tau aggregation and its interplay with amyloid-beta","volume":"129","author":"Nisbet","year":"2015","journal-title":"Acta Neuropathol"},{"issue":"228","key":"10.1016\/j.pharep.2015.07.006_bib0765","doi-asserted-by":"crossref","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharep.2015.07.006_bib0770","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coph.2013.12.002","article-title":"New applications of disease genetics and pharmacogenetics to drug development","volume":"14","author":"Roses","year":"2014","journal-title":"Curr Opin Pharmacol"},{"issue":"10","key":"10.1016\/j.pharep.2015.07.006_bib0775","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.neurol.2013.07.017","article-title":"Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial","volume":"169","author":"Mills","year":"2013","journal-title":"Rev Neurol (Paris)"},{"issue":"10","key":"10.1016\/j.pharep.2015.07.006_bib0780","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/0165-6147(91)90609-V","article-title":"Amyloid deposition as the central event in the aetiology of Alzheimer's disease","volume":"12","author":"Hardy","year":"1991","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0785","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0955-0674(00)00172-1","article-title":"Going new places using an old MAP: tau, microtubules and human neurodegenerative disease","volume":"13","author":"Garcia","year":"2001","journal-title":"Curr Opin Cell Biol"},{"issue":"4","key":"10.1016\/j.pharep.2015.07.006_bib0790","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.bcp.2013.12.008","article-title":"Tau-aggregation inhibitor therapy for Alzheimer's disease","volume":"88","author":"Wischik","year":"2014","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0795","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/nan.12192","article-title":"Invited review: drug development for tauopathies","volume":"41","author":"Gruninger","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0800","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.0406361102","article-title":"Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.pharep.2015.07.006_bib0805","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jalz.2009.05.246","article-title":"Tau vaccine: active immunization with misfolded tau protein attenuates tau pathology in the transgenic rat model of tauopathy","volume":"5","author":"Novak","year":"2009","journal-title":"Alzheimer's Dement"},{"issue":"8","key":"10.1016\/j.pharep.2015.07.006_bib0810","doi-asserted-by":"crossref","first-page":"72301","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein Tau, assessed in tau.P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLOS ONE"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0815","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of Alzheimer's disease with the GSK-3 inhibitor tideglusib: a pilot study","volume":"33","author":"del Ser","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.pharep.2015.07.006_bib0820","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3beta inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo","volume":"35","author":"Sereno","year":"2009","journal-title":"Neurobiol Dis"},{"issue":"4","key":"10.1016\/j.pharep.2015.07.006_bib0825","doi-asserted-by":"crossref","first-page":"P689","DOI":"10.1016\/j.jalz.2013.04.359","article-title":"A phase II randomized, double-blind, parallel group, 26-week study of GSK-3 inhibitor tideglusib in Alzheimer's disease (argo trial)","volume":"9","author":"del Ser","year":"2013","journal-title":"Alzheimer's Dement"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0830","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3233\/JAD-141959","article-title":"A phase II trial of tideglusib in Alzheimer's disease","volume":"45","author":"Lovestone","year":"2015","journal-title":"J Alzheimers Dis"},{"issue":"2","key":"10.1016\/j.pharep.2015.07.006_bib0835","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3233\/JAD-2012-121294","article-title":"Intranasal insulin ameliorates tau hyperphosphorylation in a rat model of type 2 diabetes","volume":"33","author":"Yang","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"4","key":"10.1016\/j.pharep.2015.07.006_bib0840","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3233\/JAD-122308","article-title":"Sex and ApoE genotype differences in treatment response to two doses of intranasal insulin in adults with mild cognitive impairment or Alzheimer's disease","volume":"35","author":"Claxton","year":"2013","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"10.1016\/j.pharep.2015.07.006_bib0845","doi-asserted-by":"crossref","first-page":"323","DOI":"10.3233\/JAD-2008-13309","article-title":"Intranasal insulin administration dose-dependently modulates verbal memory and plasma amyloid-beta in memory-impaired older adults","volume":"13","author":"Reger","year":"2008","journal-title":"J Alzheimers Dis"},{"issue":"6","key":"10.1016\/j.pharep.2015.07.006_bib0850","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/01.WNL.0000265401.62434.36","article-title":"Intranasal insulin improves cognition and modulates beta-amyloid in early AD","volume":"70","author":"Reger","year":"2008","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.pharep.2015.07.006_bib0855","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1017\/S146114570999054X","article-title":"Signalling pathways associated with 5-HT6 receptors: relevance for cognitive effects","volume":"13","author":"Marcos","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"issue":"2","key":"10.1016\/j.pharep.2015.07.006_bib0860","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1358\/dof.2014.039.02.2103730","article-title":"The 5-HT6 receptor antagonism approach in Alzheimer's disease","volume":"39","author":"Marazziti","year":"2014","journal-title":"Drugs Future"},{"issue":"11","key":"10.1016\/j.pharep.2015.07.006_bib0865","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1474-4422(14)70198-X","article-title":"Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"13","author":"Wilkinson","year":"2014","journal-title":"Lancet Neurol"},{"issue":"11","key":"10.1016\/j.pharep.2015.07.006_bib0870","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S1474-4422(14)70232-7","article-title":"Idalopirdine for Alzheimer's disease: written in the stars","volume":"13","author":"Schneider","year":"2014","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.pharep.2015.07.006_bib0875","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/bjp.2008.281","article-title":"Effects of 5-HT6 receptor antagonism and cholinesterase inhibition in models of cognitive impairment in the rat","volume":"155","author":"Marcos","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"4","key":"10.1016\/j.pharep.2015.07.006_bib0880","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jalz.2013.04.267","article-title":"A clinical phase II study of LU AE58054 added to stable donepezil treatment in patients with moderate Alzheimer's disease","volume":"9","author":"Wilkinson","year":"2013","journal-title":"Alzheimer's Dement"},{"issue":"5","key":"10.1016\/j.pharep.2015.07.006_bib0885","doi-asserted-by":"crossref","first-page":"374","DOI":"10.2174\/156720510791383831","article-title":"Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease","volume":"7","author":"Maher-Edwards","year":"2010","journal-title":"Curr Alzheimer Res"},{"issue":"5","key":"10.1016\/j.pharep.2015.07.006_bib0890","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2515\/therapie\/2010058","article-title":"The histaminergic system: a target for innovative treatments of cognitive deficits","volume":"65","author":"Motawaj","year":"2010","journal-title":"Therapie"},{"issue":"6","key":"10.1016\/j.pharep.2015.07.006_bib0895","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/bjp.2008.147","article-title":"The histamine H3 receptor: an attractive target for the treatment of cognitive disorders","volume":"154","author":"Esbenshade","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0900","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1124\/jpet.112.194126","article-title":"Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist","volume":"343","author":"Esbenshade","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.pharep.2015.07.006_bib0905","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1111\/bcp.12281","article-title":"The H3 antagonist ABT-288 is tolerated at significantly higher exposures in subjects with schizophrenia than in healthy volunteers","volume":"77","author":"Othman","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.pharep.2015.07.006_bib0910","doi-asserted-by":"crossref","first-page":"959","DOI":"10.3233\/JAD-140291","article-title":"A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia","volume":"42","author":"Haig","year":"2014","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0915","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2174\/1567205010666131212110148","article-title":"A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease","volume":"11","author":"Grove","year":"2014","journal-title":"Curr Alzheimer Res"},{"key":"10.1016\/j.pharep.2015.07.006_bib0920","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2377-14-12","article-title":"Effect of TTP488 in patients with mild to moderate Alzheimer's disease","volume":"14","author":"Burstein","year":"2014","journal-title":"BMC Neurol"},{"issue":"2","key":"10.1016\/j.pharep.2015.07.006_bib0925","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.neuropharm.2011.10.024","article-title":"EVP-6124, a novel and selective alpha7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of alpha7 nicotinic acetylcholine receptors","author":"Prickaerts","year":"2012","journal-title":"Neuropharmacology"},{"issue":"9","key":"10.1016\/j.pharep.2015.07.006_bib0930","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/jnnp.74.9.1200","article-title":"Intrathecal inflammation precedes development of Alzheimer's disease","volume":"74","author":"Tarkowski","year":"2003","journal-title":"Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.pharep.2015.07.006_bib0935","doi-asserted-by":"crossref","DOI":"10.1186\/1742-2094-9-99","article-title":"Early intervention with a small molecule inhibitor for tumor necrosis factor-alpha prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease","volume":"9","author":"Gabbita","year":"2012","journal-title":"J Neuroinflammation"},{"issue":"3","key":"10.1016\/j.pharep.2015.07.006_bib0940","doi-asserted-by":"crossref","first-page":"197","DOI":"10.47276\/lr.78.3.197","article-title":"The role of thalidomide in the management of erythema nodosum leprosum","volume":"78","author":"Walker","year":"2007","journal-title":"Lepr Rev"},{"issue":"20","key":"10.1016\/j.pharep.2015.07.006_bib0945","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.1182\/blood-2014-09-568915","article-title":"Frontline therapy of multiple myeloma","volume":"125","author":"Moreau","year":"2015","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.pharep.2015.07.006_bib0950","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.2174\/156802612801784407","article-title":"Thalidomide chemistry, therapeutic potential and oxidative stress induced teratogenicity","volume":"12","author":"Kumar","year":"2012","journal-title":"Curr Top Med Chem"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0955","doi-asserted-by":"crossref","first-page":"1","DOI":"10.55782\/ane-2004-1486","article-title":"Thalidomide-based TNF-alpha inhibitors for neurodegenerative diseases","volume":"64","author":"Greig","year":"2004","journal-title":"Acta Neurobiol Exp (Wars)"},{"issue":"7","key":"10.1016\/j.pharep.2015.07.006_bib0960","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.neubiorev.2007.04.004","article-title":"Molecular connexions between dementia and diabetes","volume":"31","author":"Cole","year":"2007","journal-title":"Neurosci Biobehav Rev"},{"issue":"9","key":"10.1016\/j.pharep.2015.07.006_bib0965","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/nm919","article-title":"Glucagon-like peptide-1 receptor is involved in learning and neuroprotection","volume":"9","author":"During","year":"2003","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0970","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.bbr.2009.06.035","article-title":"Impairment of synaptic plasticity and memory formation in GLP-1 receptor KO mice: Interaction between type 2 diabetes and Alzheimer's disease","volume":"205","author":"Abbas","year":"2009","journal-title":"Behav Brain Res"},{"issue":"10","key":"10.1016\/j.pharep.2015.07.006_bib0975","first-page":"A4519","article-title":"Effects of liraglutide on neurodegeneration, blood flow and cognition in Alzheimer s disease - protocol for a controlled, randomized double-blinded trial","volume":"59","author":"Egefjord","year":"2012","journal-title":"Dan Med J"},{"issue":"10","key":"10.1016\/j.pharep.2015.07.006_bib0980","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006364","article-title":"NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease","volume":"4","author":"Lawlor","year":"2014","journal-title":"BMJ Open"},{"issue":"8","key":"10.1016\/j.pharep.2015.07.006_bib0985","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1212\/WNL.43.8.1467","article-title":"Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease","volume":"43","author":"Saunders","year":"1993","journal-title":"Neurology"},{"issue":"5123","key":"10.1016\/j.pharep.2015.07.006_bib0990","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1126\/science.8346443","article-title":"Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families","volume":"261","author":"Corder","year":"1993","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.pharep.2015.07.006_bib0995","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/geno.1998.5581","article-title":"A 4-Mb high-density single nucleotide polymorphism-based map around human APOE","volume":"54","author":"Lai","year":"1998","journal-title":"Genomics"},{"issue":"26","key":"10.1016\/j.pharep.2015.07.006_bib1000","doi-asserted-by":"crossref","first-page":"16899","DOI":"10.1073\/pnas.242603899","article-title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences","volume":"99","author":"Strausberg","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"10.1016\/j.pharep.2015.07.006_bib1005","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1074\/jbc.M111.276162","article-title":"Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons","volume":"287","author":"Chen","year":"2012","journal-title":"J Biol Chem"},{"issue":"February 2","key":"10.1016\/j.pharep.2015.07.006_bib1010","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/clpt.2012.222","article-title":"Using genetics to enable studies on the prevention of Alzheimer's disease","volume":"93","author":"Crenshaw","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.pharep.2015.07.006_bib1015","doi-asserted-by":"crossref","first-page":"e30994","DOI":"10.1371\/journal.pone.0030994","article-title":"Characterization of the poly-T variant in the TOMM40 gene in diverse populations","volume":"7","author":"Linnertz","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.pharep.2015.07.006_bib1020","doi-asserted-by":"crossref","first-page":"652","DOI":"10.4088\/JCP.13m08927","article-title":"The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers","volume":"75","author":"Ayutyanont","year":"2014","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.1016\/j.pharep.2015.07.006_bib1025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer's disease drug-development pipeline: few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res Ther"},{"issue":"3","key":"10.1016\/j.pharep.2015.07.006_bib1030","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2174\/0929867321666141106122628","article-title":"Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease","volume":"22","author":"Guzior","year":"2015","journal-title":"Curr Med Chem"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114015002868?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1734114015002868?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T20:36:12Z","timestamp":1752611772000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1016\/j.pharep.2015.07.006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S1734114015002868"],"URL":"https:\/\/doi.org\/10.1016\/j.pharep.2015.07.006","relation":{},"ISSN":["1734-1140"],"issn-type":[{"value":"1734-1140","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic strategies for Alzheimer's disease in clinical trials","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharep.2015.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier Urban & Partner Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}